| Market Capitalization (Millions $) |
3,996 |
| Shares
Outstanding (Millions) |
127 |
| Employees |
182 |
| Revenues (TTM) (Millions $) |
597 |
| Net Income (TTM) (Millions $) |
221 |
| Cash Flow (TTM) (Millions $) |
175 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Catalyst Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development and commercialization of drugs for rare neurological diseases. The company is headquartered in Coral Gables, Florida, and was founded in 200
The company's focus is on developing drugs for Lambert-Eaton Myasthenic Syndrome (LEMS), a rare autoimmune disorder that affects the neuromuscular junction. LEMS is characterized by muscle weakness and fatigue, and it affects only a small percentage of the population.
Catalyst Pharmaceuticals Inc. has one FDA-approved product on the market, Firdapse (amifampridine), which was approved by the FDA in November 2018. Firdapse is a potassium channel blocker that is used to treat adult patients with LEMS. The drug works to increase the release of acetylcholine, a neurotransmitter that is necessary for the normal function of the neuromuscular junction, thus improving muscle function in patients with LEMS.
The company's pipeline includes other drugs that target rare neurological diseases. CPP-115 is a GABA aminotransferase inhibitor, which is being developed for the treatment of epileptic encephalopathies, a group of rare and severe epileptic disorders.
Catalyst Pharmaceuticals Inc. has a strong financial position, with no debt and a cash balance of over $160 million as of the end of 2020. This stable financial position puts the company in a good position for the further development of its drug pipeline.
The company has faced some controversy in the past regarding the pricing of Firdapse, with critics arguing that the $375,000 per year price tag is too high. Catalyst Pharmaceuticals Inc. has defended its pricing, arguing that the drug is a life-changing treatment for patients with LEMS and is competitively priced compared to other rare disease treatments.
Overall, Catalyst Pharmaceuticals Inc. is a small but well-respected biopharmaceutical company focused on the development of drugs for rare neurological diseases. With its strong financial position and promising drug pipeline, it is poised for continued growth and success.
Company Address: 355 Alhambra Circle Coral Gables 33134 FL
Company Phone Number: 420-3200 Stock Exchange / Ticker: NASDAQ CPRX
|
%
1.07% 
66.18 %